GlassScriptPhysician profile
Mark P Lebeis
NPI 1558391003
$1,019.11
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $100 · 2021: $68.38 · 2022: $21.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $165.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $132.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.80 | 2019 | |
| Amgen INC. | $94.33 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.17 | 2019-2022 | |
| Edwards Lifesciences Corporation | $60.97 | 2019-2020 | |
| Astellas Pharma US INC | $60.47 | 2019 | |
| Csl Behring | $51.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $48.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.07 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $37.87 | 2019-2020 | |
| Lundbeck LLC | $30.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.28 | 2021 | |
| Merck Sharp & Dohme LLC | $16.96 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.73 | 2019 | |
| Boston Scientific Corporation | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lebeis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.